Edgar Filing: CANCER GENETICS, INC - Form 4

CANCER GENETICS, INC Form 4										
October 15, 2013										
FORM 4 UNITED				NOD	CONDUCCION	OMB APPROVAL				
Washington, D.C. 20549							OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or	NGES IN BENEFICIAL OWNERSHIP OF SECURITIES					Expires: Estimated burden hou response	ed average hours per			
abligations	suant to Section 1 a) of the Public U 30(h) of the In	Itility Hol	ding Cor	npany	y Act	of 1935 or Section				
(Print or Type Responses)										
1. Name and Address of Reporting El Naggar Jane Houldsworth	Symbol	suer Name and Ticker or Trading ol CER GENETICS, INC [CGIX]			5. Relationship of Reporting Person(s) to Issuer					
(Last) (First) (I	of Earliest Transaction				(Check all applicable)					
201 ROUTE 17 NORTH, 2N FLOOR	h/Day/Year))/2013				Director 10% Owner Officer (give title Other (specify below) vP of Research and Development					
(Street)	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)			1		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
RUTHERFORD, NJ 07070							More than One R			
(City) (State)	(Zip) Tab	le I - Non-l	Derivative	Secur	ities A	cquired, Disposed o	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D) 4 and 5 (A) or		Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Report on a separate line	e for each class of sec	urities bene	ficially own	ned dir	rectly o	or indirectly.				

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionDerivative		Expiration Date	Underlying Securities 1	
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

Edgar Filing: CANCER GENETICS, INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)) (Instr. 8)	Acquired (or Dispose (D) (Instr. 3, 4 and 5)	ed of				(
				Code V	(A)	(D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Stock Option (right to buy)	\$ 15.39	10/10/2013		А	10,000	<u>(1)</u>	10/09/2023	Common Stock	10,000		
Reporting Owners											
Reporting Owner Name / Address	ddress		Relatio	onships							
		Director	r 10% Owner	Officer			Other				
	r Jane Houldsw TE 17 NORTH			VP of Res	search and	l Development					

Signatures

RUTHERFORD, NJ 07070

2ND FLOOR

/s/ Jane Houldsworth by Elizabeth Czerepak, Attorney-in-Fact 10/15/2013 <u>**</u>Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 20% of the shares underlying the option vest on the one year anniversary of the date on which the option was granted, and the remaining shares vest in 48 equal monthly installments commencing one month following the one year anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.